Recent research have focused on the convergence of GLP|GIP|GCGR activator therapies and DA signaling. While GCGR agonists are increasingly employed for managing type 2 diabetes mellitus, their unexpected consequences on reinforcement circuits, specifically mediated by dopaminergic pathways, are gaining substantial focus. This paper details a con… Read More